{"transactions":[{"id":680556,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:25:46.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":86.96,"value":173920.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":31600,"source":{"system":"sec-edgar","filing":"0001242615-26-000002","document":"wk-form4_1787261143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261526000002/wk-form4_1787261143.xml","form_type":"4"}},{"id":680555,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21398,"kind":"person","name":"PERRY MICHAEL S","position":1,"cik":"0001250379","reported_name":"PERRY MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-20T21:22:21.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":11600,"price":87.3,"value":1012680.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":111459,"source":{"system":"sec-edgar","filing":"0001250379-26-000002","document":"wk-form4_1787260939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000125037926000002/wk-form4_1787260939.xml","form_type":"4"}},{"id":735152,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37458,"kind":"person","name":"Cohen Matthew Gregory","position":1,"cik":"0002141314","reported_name":"Cohen Matthew Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T01:44:15.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":11882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years."}],"balance_after":11882,"source":{"system":"sec-edgar","filing":"0002141314-26-000004","document":"wk-form4_1781747052.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000214131426000004/wk-form4_1781747052.xml","form_type":"4"}},{"id":779900,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:05:44.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":2970,"price":76.88,"value":228333.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":52012,"source":{"system":"sec-edgar","filing":"0001767584-26-000002","document":"wk-form4_1778799941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000176758426000002/wk-form4_1778799941.xml","form_type":"4"}},{"id":801347,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51415,"kind":"person","name":"Apel Daniel Joseph","position":1,"cik":"0002081169","reported_name":"Apel Daniel Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-24T22:44:42.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":8730,"price":71.92,"value":627861.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":162905,"source":{"system":"sec-edgar","filing":"0000879407-26-000039","document":"wk-form4_1777070680.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000039/wk-form4_1777070680.xml","form_type":"4"}},{"id":801346,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51415,"kind":"person","name":"Apel Daniel Joseph","position":1,"cik":"0002081169","reported_name":"Apel Daniel Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-24T22:44:42.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":1157,"price":70.45,"value":81510.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":171635,"source":{"system":"sec-edgar","filing":"0000879407-26-000039","document":"wk-form4_1777070680.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000039/wk-form4_1777070680.xml","form_type":"4"}},{"id":801345,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51415,"kind":"person","name":"Apel Daniel Joseph","position":1,"cik":"0002081169","reported_name":"Apel Daniel Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-24T22:44:42.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":3208,"price":70.11,"value":224912.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":172792,"source":{"system":"sec-edgar","filing":"0000879407-26-000039","document":"wk-form4_1777070680.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000039/wk-form4_1777070680.xml","form_type":"4"}},{"id":801342,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-24T22:38:34.000Z","date":"2026-04-23","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":75,"value":750000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":226958,"source":{"system":"sec-edgar","filing":"0001830755-26-000007","document":"wk-form4_1777070312.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000007/wk-form4_1777070312.xml","form_type":"4"}},{"id":854815,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-09T23:00:06.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":64.19,"value":641900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":236958,"source":{"system":"sec-edgar","filing":"0001830755-26-000006","document":"wk-form4_1773097203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000006/wk-form4_1773097203.xml","form_type":"4"}},{"id":943672,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:55.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units which will vest in four equal annual installments."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":246958,"source":{"system":"sec-edgar","filing":"0001830755-26-000004","document":"wk-form4_1767915953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000004/wk-form4_1767915953.xml","form_type":"4"}},{"id":943666,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51415,"kind":"person","name":"Apel Daniel Joseph","position":1,"cik":"0002081169","reported_name":"Apel Daniel Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:49.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units which will vest in four equal annual installments."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":176200,"source":{"system":"sec-edgar","filing":"0002081169-26-000002","document":"wk-form4_1767915947.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000208116926000002/wk-form4_1767915947.xml","form_type":"4"}},{"id":943660,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:43.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying restricted stock units which will vest in four equal annual installments."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":547408,"source":{"system":"sec-edgar","filing":"0001627183-26-000003","document":"wk-form4_1767915940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000003/wk-form4_1767915940.xml","form_type":"4"}},{"id":943659,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:43.000Z","date":"2026-01-06","kind":"gift","planned":false,"acquired":false,"shares":440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":472408,"source":{"system":"sec-edgar","filing":"0001627183-26-000003","document":"wk-form4_1767915940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000003/wk-form4_1767915940.xml","form_type":"4"}},{"id":943658,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:43.000Z","date":"2026-01-06","kind":"gift","planned":false,"acquired":false,"shares":440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":472848,"source":{"system":"sec-edgar","filing":"0001627183-26-000003","document":"wk-form4_1767915940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000003/wk-form4_1767915940.xml","form_type":"4"}},{"id":943657,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:43.000Z","date":"2026-01-06","kind":"gift","planned":false,"acquired":false,"shares":540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":473288,"source":{"system":"sec-edgar","filing":"0001627183-26-000003","document":"wk-form4_1767915940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000003/wk-form4_1767915940.xml","form_type":"4"}},{"id":943656,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:43.000Z","date":"2026-01-06","kind":"gift","planned":false,"acquired":false,"shares":540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":473828,"source":{"system":"sec-edgar","filing":"0001627183-26-000003","document":"wk-form4_1767915940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000003/wk-form4_1767915940.xml","form_type":"4"}},{"id":943655,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-08T23:45:43.000Z","date":"2026-01-06","kind":"gift","planned":false,"acquired":false,"shares":540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":474368,"source":{"system":"sec-edgar","filing":"0001627183-26-000003","document":"wk-form4_1767915940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000003/wk-form4_1767915940.xml","form_type":"4"}},{"id":953728,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":46,"price":68,"value":3128.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":474908,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953727,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":2336,"price":64.04,"value":149597.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":474954,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953726,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":5873,"price":62.91,"value":369470.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.54 to $63.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":477290,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953725,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":900,"price":62.25,"value":56025.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":483163,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953724,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":600,"price":61.12,"value":36672.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.75 to $61.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":484063,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953723,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":313,"price":68,"value":21284.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F4","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":484663,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953722,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":900,"price":66.01,"value":59409.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F4","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":484976,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953721,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":2700,"price":64.44,"value":173988.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F4","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":485876,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953720,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":11842,"price":63.84,"value":755993.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F4","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.41 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":488576,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953719,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":13451,"price":62.96,"value":846874.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F4","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":500418,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953718,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":6164,"price":62.23,"value":383585.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F4","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":513869,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953717,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":4368,"price":61.2,"value":267321.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F4","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":520033,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953716,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2025-12-31","kind":"gift","planned":true,"acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":524401,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953715,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2025-12-31","kind":"gift","planned":true,"acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":524961,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953714,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2025-12-31","kind":"gift","planned":true,"acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":525521,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953713,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2025-12-31","kind":"gift","planned":true,"acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":526081,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953712,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":69798,"kind":"person","name":"O'Brien Patrick","position":1,"cik":"0001627183","reported_name":"O'Brien Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2026-01-06T02:50:17.000Z","date":"2025-12-31","kind":"gift","planned":true,"acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift to relatives"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":526641,"source":{"system":"sec-edgar","filing":"0001627183-26-000001","document":"wk-form4_1767667814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162718326000001/wk-form4_1767667814.xml","form_type":"4"}},{"id":953711,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:41:44.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":309,"price":68,"value":21012.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":171958,"source":{"system":"sec-edgar","filing":"0001830755-26-000002","document":"wk-form4_1767667301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000002/wk-form4_1767667301.xml","form_type":"4"}},{"id":953710,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:41:44.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":437,"price":65.97,"value":28828.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.90 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":172267,"source":{"system":"sec-edgar","filing":"0001830755-26-000002","document":"wk-form4_1767667301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000002/wk-form4_1767667301.xml","form_type":"4"}},{"id":953709,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:41:44.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":1200,"price":64.49,"value":77388.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.44 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":172704,"source":{"system":"sec-edgar","filing":"0001830755-26-000002","document":"wk-form4_1767667301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000002/wk-form4_1767667301.xml","form_type":"4"}},{"id":953708,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:41:44.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":12711,"price":63.95,"value":812868.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.57 to $64.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":173904,"source":{"system":"sec-edgar","filing":"0001830755-26-000002","document":"wk-form4_1767667301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000002/wk-form4_1767667301.xml","form_type":"4"}},{"id":953707,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:41:44.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":14792,"price":63.01,"value":932043.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.61 to $63.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":186615,"source":{"system":"sec-edgar","filing":"0001830755-26-000002","document":"wk-form4_1767667301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000002/wk-form4_1767667301.xml","form_type":"4"}},{"id":953706,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:41:44.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":6090,"price":62.28,"value":379285.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":201407,"source":{"system":"sec-edgar","filing":"0001830755-26-000002","document":"wk-form4_1767667301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000002/wk-form4_1767667301.xml","form_type":"4"}},{"id":953705,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:41:44.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":4625,"price":61.24,"value":283235.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.66, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":207497,"source":{"system":"sec-edgar","filing":"0001830755-26-000002","document":"wk-form4_1767667301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075526000002/wk-form4_1767667301.xml","form_type":"4"}},{"id":953704,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:39:41.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":5771,"price":66.39,"value":383136.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.21 to $66.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3792739,"source":{"system":"sec-edgar","filing":"0001423029-26-000001","document":"wk-form4_1767667178.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302926000001/wk-form4_1767667178.xml","form_type":"4"}},{"id":953703,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-06T02:39:41.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":7416,"price":65.88,"value":488566.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"Partial disposition of shares to satisfy tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.28 to $66.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3798510,"source":{"system":"sec-edgar","filing":"0001423029-26-000001","document":"wk-form4_1767667178.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302926000001/wk-form4_1767667178.xml","form_type":"4"}},{"id":957645,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":16545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All options were fully vested and exercisable as of January 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":6.15,"exercise_date":"2016-01-01","expiration_date":"2026-01-01","underlying":"Common Stock","underlying_shares":16545},"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957644,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":35181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All options were fully vested and exercisable as of January 1, 2016."}],"balance_after":16545,"derivative":{"exercise_price":6.15,"exercise_date":"2016-01-01","expiration_date":"2026-01-01","underlying":"Common Stock","underlying_shares":35181},"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957643,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":16545,"price":68.69,"value":1136476.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.10 to $69.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3805926,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957642,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":35181,"price":69.33,"value":2439098.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.09 to $69.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3822471,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957641,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":16545,"price":6.15,"value":101751.75,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3857652,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957640,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-30T22:46:35.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":35181,"price":6.15,"value":216363.15,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3841107,"source":{"system":"sec-edgar","filing":"0001423029-25-000009","document":"wk-form4_1767134792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000009/wk-form4_1767134792.xml","form_type":"4"}},{"id":957637,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70785,"kind":"person","name":"Ferrari Mauro","position":1,"cik":"0001506045","reported_name":"Ferrari Mauro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T22:46:28.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":7530,"price":70,"value":527100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":69053,"source":{"system":"sec-edgar","filing":"0001506045-25-000007","document":"wk-form4_1767134785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000150604525000007/wk-form4_1767134785.xml","form_type":"4"}},{"id":960288,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:44.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":500,"price":68.53,"value":34265.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":56563,"source":{"system":"sec-edgar","filing":"0001553338-25-000005","document":"wk-form4_1766530901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000005/wk-form4_1766530901.xml","form_type":"4"}},{"id":960287,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:44.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":5451,"price":68.01,"value":370722.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":57063,"source":{"system":"sec-edgar","filing":"0001553338-25-000005","document":"wk-form4_1766530901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000005/wk-form4_1766530901.xml","form_type":"4"}},{"id":960286,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:44.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":2416,"price":66.66,"value":161050.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":62514,"source":{"system":"sec-edgar","filing":"0001553338-25-000005","document":"wk-form4_1766530901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000005/wk-form4_1766530901.xml","form_type":"4"}},{"id":960285,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70919,"kind":"person","name":"Vakiener Victoria","position":1,"cik":"0001826263","reported_name":"Vakiener Victoria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:37.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":1960,"price":68.39,"value":134044.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.21 to $68.53, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":35723,"source":{"system":"sec-edgar","filing":"0001826263-25-000006","document":"wk-form4_1766530895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000182626325000006/wk-form4_1766530895.xml","form_type":"4"}},{"id":960284,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70919,"kind":"person","name":"Vakiener Victoria","position":1,"cik":"0001826263","reported_name":"Vakiener Victoria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:37.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":5281,"price":67.97,"value":358949.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.36 to $68.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":37683,"source":{"system":"sec-edgar","filing":"0001826263-25-000006","document":"wk-form4_1766530895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000182626325000006/wk-form4_1766530895.xml","form_type":"4"}},{"id":960283,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70919,"kind":"person","name":"Vakiener Victoria","position":1,"cik":"0001826263","reported_name":"Vakiener Victoria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:37.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":2799,"price":66.63,"value":186497.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":42964,"source":{"system":"sec-edgar","filing":"0001826263-25-000006","document":"wk-form4_1766530895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000182626325000006/wk-form4_1766530895.xml","form_type":"4"}},{"id":960281,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":2574,"price":68.85,"value":177219.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.76 to $69.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3805926,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960280,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":10012,"price":68.33,"value":684119.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.79 to $68.75, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3808500,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960279,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":1319,"price":68.48,"value":90325.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.40 to $68.53, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3818512,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960278,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":8147,"price":68.01,"value":554077.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.59 to $68.37, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3819831,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960277,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T23:01:31.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":3979,"price":66.67,"value":265279.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3827978,"source":{"system":"sec-edgar","filing":"0001423029-25-000007","document":"wk-form4_1766530888.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000007/wk-form4_1766530888.xml","form_type":"4"}},{"id":960276,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:25.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":827,"price":68.48,"value":56632.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.38 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":33600,"source":{"system":"sec-edgar","filing":"0001242615-25-000006","document":"wk-form4_1766530882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000006/wk-form4_1766530882.xml","form_type":"4"}},{"id":960275,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:25.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":6083,"price":68.04,"value":413887.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.62 to $68.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":34427,"source":{"system":"sec-edgar","filing":"0001242615-25-000006","document":"wk-form4_1766530882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000006/wk-form4_1766530882.xml","form_type":"4"}},{"id":960274,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:25.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":3090,"price":66.7,"value":206103.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.40, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":40510,"source":{"system":"sec-edgar","filing":"0001242615-25-000006","document":"wk-form4_1766530882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000006/wk-form4_1766530882.xml","form_type":"4"}},{"id":962585,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":1981,"price":66.3,"value":131340.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.03 to $66.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3831957,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":962584,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":982,"price":65.53,"value":64350.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.48 to $65.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3833938,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":962583,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":35750,"price":64.51,"value":2306232.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.06 to $64.84, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3834920,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":962582,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T23:56:33.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":46287,"price":63.55,"value":2941538.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold exclusively to cover anticipated taxes on performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.07 to $64.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3870670,"source":{"system":"sec-edgar","filing":"0001423029-25-000005","document":"wk-form4_1766188590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000005/wk-form4_1766188590.xml","form_type":"4"}},{"id":963712,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70785,"kind":"person","name":"Ferrari Mauro","position":1,"cik":"0001506045","reported_name":"Ferrari Mauro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:40:20.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":76583,"source":{"system":"sec-edgar","filing":"0001506045-25-000005","document":"wk-form4_1766101217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000150604525000005/wk-form4_1766101217.xml","form_type":"4"}},{"id":963711,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:40:14.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":54982,"source":{"system":"sec-edgar","filing":"0001767584-25-000004","document":"wk-form4_1766101211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000176758425000004/wk-form4_1766101211.xml","form_type":"4"}},{"id":963710,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21398,"kind":"person","name":"PERRY MICHAEL S","position":1,"cik":"0001250379","reported_name":"PERRY MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:40:08.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":123059,"source":{"system":"sec-edgar","filing":"0001250379-25-000005","document":"wk-form4_1766101205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000125037925000005/wk-form4_1766101205.xml","form_type":"4"}},{"id":963709,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70919,"kind":"person","name":"Vakiener Victoria","position":1,"cik":"0001826263","reported_name":"Vakiener Victoria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:40:02.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":45763,"source":{"system":"sec-edgar","filing":"0001826263-25-000004","document":"wk-form4_1766101199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000182626325000004/wk-form4_1766101199.xml","form_type":"4"}},{"id":963708,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":39693,"kind":"person","name":"INGRAM DOUGLAS S","position":1,"cik":"0001190644","reported_name":"INGRAM DOUGLAS S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:39:56.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":46215,"source":{"system":"sec-edgar","filing":"0001190644-25-000004","document":"wk-form4_1766101193.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000119064425000004/wk-form4_1766101193.xml","form_type":"4"}},{"id":963707,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21399,"kind":"person","name":"OLUKOTUN ADEOYE Y","position":1,"cik":"0001242615","reported_name":"OLUKOTUN ADEOYE Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:39:49.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":43600,"source":{"system":"sec-edgar","filing":"0001242615-25-000004","document":"wk-form4_1766101187.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000124261525000004/wk-form4_1766101187.xml","form_type":"4"}},{"id":963706,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:35:35.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":64930,"source":{"system":"sec-edgar","filing":"0001553338-25-000003","document":"wk-form4_1766100932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000003/wk-form4_1766100932.xml","form_type":"4"}},{"id":968359,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":3221,"price":67.87,"value":218609.27,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.70 to $68.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3916957,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968358,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":166,"price":66.77,"value":11083.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.70 to $66.88, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3920178,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968357,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":1300,"price":65.77,"value":85501.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.63 to $65.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3920344,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968356,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":64.96,"value":64960.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.81 to $65.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3921644,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968355,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":6661,"price":64.29,"value":428235.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.56 to $64.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3922644,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968354,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":8476,"price":62.94,"value":533479.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.62 to $63.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3929305,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968353,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":14095,"price":62.12,"value":875581.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.72 to $62.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3937781,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968352,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":10963,"price":61.25,"value":671483.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.79 to $61.68, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3951876,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968351,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":8416,"price":60.51,"value":509252.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $59.73 to $60.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3962839,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968350,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":8147,"price":69.96,"value":569964.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.83 to $70.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3971255,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968349,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":21321,"price":69.28,"value":1477118.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.01 to $69.75, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":3979402,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968348,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":100532,"price":68.67,"value":6903532.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares sold exclusively to cover anticipated taxes on a performance awards that vested December 12, 2025. These performance awards were previously reported on form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.28 to $69.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":4000723,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":968347,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T18:14:48.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units with a grant date December 12, 2025, which will vest in four equal annual installments."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":4101255,"source":{"system":"sec-edgar","filing":"0001423029-25-000003","document":"wk-form4_1765908884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000142302925000003/wk-form4_1765908884.xml","form_type":"4"}},{"id":976893,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":21398,"kind":"person","name":"PERRY MICHAEL S","position":1,"cik":"0001250379","reported_name":"PERRY MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T23:04:27.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":16250,"price":61.03,"value":991737.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $61.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":115240,"source":{"system":"sec-edgar","filing":"0001250379-25-000003","document":"wk-form4_1765321464.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000125037925000003/wk-form4_1765321464.xml","form_type":"4"}},{"id":985696,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70785,"kind":"person","name":"Ferrari Mauro","position":1,"cik":"0001506045","reported_name":"Ferrari Mauro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T23:10:20.000Z","date":"2025-11-28","kind":"sale","planned":false,"acquired":false,"shares":8750,"price":56.39,"value":493412.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":68764,"source":{"system":"sec-edgar","filing":"0001506045-25-000003","document":"wk-form4_1764630617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000150604525000003/wk-form4_1764630617.xml","form_type":"4"}},{"id":1025683,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-03T22:15:17.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":35,"value":700000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":212122,"source":{"system":"sec-edgar","filing":"0001830755-25-000011","document":"wk-form4_1759529714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075525000011/wk-form4_1759529714.xml","form_type":"4"}},{"id":1039847,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-09-16T22:06:27.000Z","date":"2025-09-12","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":30,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":232122,"source":{"system":"sec-edgar","filing":"0001830755-25-000009","document":"wk-form4_1758060385.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075525000009/wk-form4_1758060385.xml","form_type":"4"}},{"id":1048714,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-09-04T21:37:01.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":25,"value":375000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":247122,"source":{"system":"sec-edgar","filing":"0001830755-25-000007","document":"wk-form4_1757021819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075525000007/wk-form4_1757021819.xml","form_type":"4"}},{"id":1065908,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-15T21:59:02.000Z","date":"2025-08-15","kind":"sale","planned":true,"acquired":false,"shares":9389,"price":20,"value":187780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":262122,"source":{"system":"sec-edgar","filing":"0001830755-25-000005","document":"wk-form4_1755295139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075525000005/wk-form4_1755295139.xml","form_type":"4"}},{"id":1065907,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":51414,"kind":"person","name":"Hamilton James C","position":1,"cik":"0001830755","reported_name":"Hamilton James C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-08-15T21:59:02.000Z","date":"2025-08-13","kind":"sale","planned":true,"acquired":false,"shares":611,"price":20,"value":12220.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":271511,"source":{"system":"sec-edgar","filing":"0001830755-25-000005","document":"wk-form4_1755295139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000183075525000005/wk-form4_1755295139.xml","form_type":"4"}},{"id":1173640,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-11","kind":"sale","planned":false,"acquired":false,"shares":50800,"price":11.49,"value":583692.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3921255,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173639,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-10","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":10.87,"value":543500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":3972055,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173638,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":1617,"price":11.76,"value":19015.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 11.49 to $ 12.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":4022055,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173637,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":3400,"price":10.75,"value":36550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 10.51 to $ 11.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":4023672,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}},{"id":1173636,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":70471,"kind":"person","name":"Anzalone Christopher Richard","position":1,"cik":"0001423029","reported_name":"Anzalone Christopher Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-11T22:20:07.000Z","date":"2025-04-09","kind":"sale","planned":false,"acquired":false,"shares":35305,"price":9.93,"value":350578.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of securities to cover taxes associated with the vesting of restricted stock awards"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 9.67 to $ 10.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":4027072,"source":{"system":"sec-edgar","filing":"0001628280-25-017592","document":"wk-form4_1744410000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828025017592/wk-form4_1744410000.xml","form_type":"4"}}],"next_cursor":"2025-04-11T22:20:07.000000Z,1173636"}